LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Hypomethylating agent (HMA) treatment as a bridge to allogeneic hematopoietic cell transplantation (HCT) for relapsed/refractory acute myeloid leukemia (RR-AML).

Photo by nci from unsplash

7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re... Click to show full abstract

7033Background: Outcomes for patients (pts) with RR-AML are poor, with limited treatment options. Salvage HMA therapy has been explored for RR-AML but is often considered palliative. We examined re...

Keywords: treatment bridge; hypomethylating agent; treatment; hma treatment; agent hma; bridge allogeneic

Journal Title: Journal of Clinical Oncology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.